Document is current
Any future updates will be listed below
-
Authors
Futamura, Manabu https://orcid.org/0000-0001-5622-8352
Oba, Mari https://orcid.org/0000-0001-8374-8038
Masuda, Norikazu https://orcid.org/0000-0002-7302-0278
Bando, Hiroko
Okada, Morihito
Yamamoto, Yutaka
Kin, Takanori
Saeki, Toshiaki
Nagashima, Takeshi
Kuwayama, Takashi
Toh, Uhi
Hirano, Akira
Inokuchi, Masafumi
Yamagami, Kazuhiko
Mizuno, Yutaka
Kojima, Yasuyuki https://orcid.org/0000-0002-9991-0228
Nakayama, Takahiro
Yasojima, Hiroyuki
Ohno, Shinji
-
Funding
Funding for this research was provided by:
JBCRG
Taiho Pharmaceutical
- License Information
-
More Information
Article History
Received: 18 October 2020
Accepted: 8 March 2021
First Online: 3 April 2021
Declarations
:
: MF-Remuneration: Chugai, Taiho, Takeda, Novartis, and Eisai. NM-Remuneration: Chugai, AstraZeneca, Pfizer, Eli-Lilly, Eisai, Takeda, Kyowa-Kirin, MSD, Novartis, Nippon-Kayaku, and Daiichi-Sankyo. Funding: Chugai. HB-Remuneration: AstraZeneca, Eisai, Kyowa-Kirin, Taiho, Chugai, Nippon-Kayaku, Pfizer, and Novartis. YY-Remuneration and Funds: Novartis, Nippon-Kayaku, Kyowa-Kirin, Taiho, and Chugai. TS-Remuneration: Ono, Kyowa-Kirin. Funding: Taiho, AstraZeneca, Chugai, and Eisai. UT-Remuneration: Chugai, Eisai, and Kyowa-Kirin. Grant: Chugai, Eisai, Taiho, Daichi-Sankyo, Nippon-Kayaku, and Kyowa-Kirin. YK-Remuneration: Chugai, Novartis, Daiichi-Sankyo, Pfizer, Eli-Lilly, AstraZeneca, Kyowa-Kirin, and Eisai. TN-Remuneration: Chugai, Eli Lilly, Novartis, AstraZeneca, and Daiichi-Sankyo. SO-Remuneration: Chugai, Eisai, Eli-Lilly, Pfizer, Taiho, and AstraZeneca. Funding: Taiho and Eisai.
: This study was conducted in accordance with the Declaration of Helsinki and approved by the review board or ethical committee of each participating institute.
: This meta-analysis used only existing information as described in the ‘‘Ethical Guidelines for Epidemiology Research’’ co-published by the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labour, and Welfare of Japan. The study purpose, methods, collection, and usage of data were published on a poster in each institution relevant to each subject population to give the opportunity to opt-out. Thus, written informed consent was not necessary.
